3158-71-2

Usage

Uses

Used in Pharmaceutical Industry:
4-Cyclopropylaniline is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs and medicinal compounds. Its unique structure allows for the creation of a variety of chemical entities that can target specific biological pathways.
Used in Agrochemical Industry:
In the agrochemical sector, 4-Cyclopropylaniline is utilized as an intermediate in the production of agrochemicals, such as pesticides and herbicides. Its role in these applications is to provide a structural foundation for the development of compounds that can effectively control pests and weeds in agricultural settings.
Used in Organic Synthesis Research:
4-Cyclopropylaniline serves as a valuable building block in organic synthesis research, where it is used to explore new chemical reactions and pathways. Its cyclopropyl group offers unique reactivity and can be manipulated to create a wide range of organic compounds for various applications.
Used in Industrial Applications:
In industrial applications, 4-Cyclopropylaniline is employed as a precursor to other organic compounds, contributing to the production of specialty chemicals, dyes, and other materials. Its versatility in synthesis makes it a useful component in the development of new industrial products.
Safety Note:
It is important to handle 4-Cyclopropylaniline with care due to its potential harmful effects if inhaled, swallowed, or comes into contact with the skin and eyes. Proper safety measures should be taken during its production, use, and disposal to minimize risks to human health and the environment.

InChI:InChI=1/C9H11N/c10-9-5-3-8(4-6-9)7-1-2-7/h3-7H,1-2,10H2

Upstream product

• 6921-44-4 4-nitrophenylcyclopropane 
• 555-21-5 4-Nitrophenylacetonitrile 
• 408328-42-7 1-(4-nitrophenyl)-1-cyclopropylcarbonitrile 
• 540-37-4 p-aminoiodobenzene 
• 411235-57-9 cyclopropylboronic acid 
• 34063-53-1 p-nitrobenzyl phenyl sulfone 
• 23348-99-4 1-(4-nitrophenyl)cyclopropane-1-carboxylic acid 
• 302333-80-8 (4-cyclopropylphenyl)boronic acid 
• 873-49-4 cyclopropylbenzene 
• 586-78-7 para-nitrophenyl bromide 
• 58678-84-5 1-(4-Nitrophenyl)-1,3-propyldinitrat 
• 58678-85-6 1-(4-Nitrophenyl)-1,3-dibrompropan 

Downstream Products

• 1258233-52-1 1-(4-cyclopropylphenyl)-2,5-bis(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrrolidine 
• 167404-32-2 4-cyclopropylbenzenesulfonyl chloride 
• 1124-14-7 1-bromo-4-cyclopropylbenzene 

Relevant academic research and scientific papers

IMIDAZOPYRIDINE DERIVATIVE COMPOUNDS AND USE OF SAME

One aspect of the present invention provides a compound selected from among a compound of chemical formula 1 having lysine-specific demethylase-1 (LSD1) inhibitory activity, and a tautomer, a stereoisomer, and a solvate thereof, and pharmaceutically accep

CHEMICAL COMPOUNDS

The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the disclosure have activity as Janus kinase (JAK) inhibitors and are useful in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK by administering a compound herein described.

Preparation method of cycloalkane compound

The invention provides a preparation method of a cycloalkane compound, and concretely provides a new cycloalkane construction method for preparing a compound represented by formula I. The preparationmethod is green and environment-friendly.

Cu(II)-Mediated N-H and N-Alkyl Aryl Amination and Olefin Aziridination

Cu(II)-mediated direct NH2 and NH alkyl aryl aminations and olefin aziridinations are described. These room-temperature, one-pot, environmentally friendly procedures replace costly Rh2 catalysts and, in some instances, display important differences with comparable Rh2- and Fe-supported reactions.

PYRAZOLE DERIVATIVE COMPOUND AND USE THEREOF

Provided is a compound represented by Formula 1 having an inhibitory activity on lysine-specific demethylase-1 (LSD1), an optical isomer, a solvate, a tautomer, or a pharmaceutically acceptable salt thereof, which is effective in preventing or treating a

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

Metal Nanoparticles Catalyzed Selective Carbon-Carbon Bond Activation in the Liquid Phase

Understanding the C-C bond activation mechanism is essential for developing the selective production of hydrocarbons in the petroleum industry and for selective polymer decomposition. In this work, ring-opening reactions of cyclopropane derivatives under hydrogen catalyzed by metal nanoparticles (NPs) in the liquid phase were studied. 40-atom rhodium (Rh) NPs, encapsulated by dendrimer molecules and supported in mesoporous silica, catalyzed the ring opening of cyclopropylbenzene at room temperature under hydrogen in benzene, and the turnover frequency (TOF) was higher than other metals or the Rh homogeneous catalyst counterparts. Comparison of reactants with various substitution groups showed that electron donation on the three-membered ring boosted the TOF of ring opening. The linear products formed with 100% selectivity for ring opening of all reactants catalyzed by the Rh NP. Surface Rh(0) acted as the active site in the NP. The capping agent played an important role in the ring-opening reaction kinetics. Larger particle size tended to show higher TOF and smaller reaction activation energy for Rh NPs encapsulated in either dendrimer or poly(vinylpyrrolidone). The generation/size of dendrimer and surface group also affected the reaction rate and activation energy.

IMMUNOREGULATORY AGENTS

Compounds that modulate the oxidoreductase enzyme indoleamine 2,3- dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases,

SUBSTITUTED TRICYCLIC COMPOUNDS WITH ACTIVITY TOWARDS EP1 RECEPTORS

The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP1 receptor as well as to pharmaceutical compositions comprising them.

SUBSTITUTED TRICYCLIC COMPOUNDS WITH ACTIVITY TOWARDS EP1 RECEPTORS

The present invention belongs to the field of EPl receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EPl receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EPl receptor as well as to pharmaceutical compositions comprising them.